HEALTHCARE · NSE/BSE: SUNPHARMA

Sun Pharmaceutical Earnings Summary — Q1 FY2027

Sentiment: Positive

AI-generated summary

Generated 2026-10-22

Business Intelligence Report

Sun Pharmaceutical Q1 FY2027 results: Profit up +27.0% YoY; revenue grew +10.5% YoY; OPM 28.9%.

Quarterly Business Intelligence

Q1 FY2027

Financials from Financial Intelligence · data as of 2026-06-30

Revenue

₹15,300 Cr

QoQ +4.7%YoY +10.5%

Net Profit

₹2,895 Cr

QoQ +6.7%YoY +27.0%

Operating Profit

₹4,418 Cr

QoQ +11.7%YoY +2.7%

Operating Margin

28.9%

QoQ +181 bpsYoY -219 bps

AI Quarterly Scorecard™

/ 100

Healthy

Revenue Momentum75

Profit Growth77

Margin Expansion59

Growth Consistency72

Operating Efficiency50

Financial Stability81

Computed deterministically from the last 10 reported quarters.

Quarterly Business Momentum

Revenue & Growth

Revenue grew 4.7% sequentially in Q1 FY2027.
Revenue of ₹15,300 Cr is 10.5% higher year-on-year.
Revenue has compounded at 11.5% annualised over the last 10 quarters.

Profitability

Net profit of ₹2,895 Cr is 27.0% above the same quarter last year.
Profit growth is outpacing revenue growth, pointing to positive operating leverage.
Net profit has compounded at 3.9% annualised across the period.

Margins

Operating margin stands at 28.9% in Q1 FY2027.
Operating margin compressed by 219 bps year-on-year.
Over the last two years operating margin has expanded by 36 bps.
PBT margin is 26.8%.

Operating Efficiency

Expenses grew 14.0% against revenue growth of 10.5%.
Operating profit of ₹4,418 Cr is 2.7% higher year-on-year.
Operating leverage has been under pressure recently.

Overall Momentum

6 of the last 6 measured quarters delivered year-on-year revenue growth.
Overall quarterly business momentum scores 69/100 (Healthy) on the latest 10 quarters.
Business momentum remains positive heading into the next quarter.

Quarterly Financials

Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %

Metric	Trend	Latest Q1 FY2027	Q4 FY2026	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Revenue	Stable	15,300	14,612	15,521	14,478	13,851	12,959	13,675	13,291	12,653	11,983
Expenses	Stable	10,882	10,658	10,572	9,951	9,550	9,243	9,666	9,352	9,045	8,948
Operating Profit	Improving	4,418	3,954	4,948	4,527	4,302	3,716	4,009	3,939	3,608	3,035
Operating Margin	Stable	28.9%	27.1%	31.9%	31.3%	31.1%	28.7%	29.3%	29.6%	28.5%	25.3%
Other Income	Volatile	520	459	89	470	-354	251	149	354	533	504
Interest	Improving	100	86	78	100	75	49	52	69	62	74
Depreciation	Stable	739	775	732	730	701	664	631	626	655	650
Profit Before Tax	Improving	4,099	3,551	4,227	4,168	3,173	3,254	3,476	3,598	3,424	2,816
Tax	Volatile	1,188	828	826	1,031	870	1,094	559	567	552	149
Net Profit	Stable	2,895	2,714	3,369	3,118	2,279	2,150	2,903	3,040	2,836	2,655
Net Margin	Stable	18.9%	18.6%	21.7%	21.5%	16.4%	16.6%	21.2%	22.9%	22.4%	22.1%

Source: Financial Intelligence (Structured Quarterly Data)•Latest Quarter: Q1 FY2027•Figures in ₹ Crore • Margins in %•Automatically updated from Financial Intelligence · 2026-06-30

Key Takeaways

Profit up +27.0% YoY; revenue grew +10.5% YoY; OPM 28.9%.

Official Quarterly Documents

Earnings Press Release

Official quarterly earnings release published by the company.

Press Release not available.

Earnings Call Transcript

Management discussion and analyst Q&A.

This summary is AI-generated from Sun Pharmaceutical's latest quarterly filing and earnings call. For informational purposes only — not investment advice.